EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
08 Diciembre 2023 - 3:01PM
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed
to developing and commercializing therapeutics to improve the lives
of patients with serious retinal diseases, today announced the
closing of its previously announced underwritten public offering of
13,529,411 shares of its common stock, which includes the exercise
in full by the underwriters of their option to purchase an
additional 1,764,705 shares of common stock, at the public offering
price of $17.00 per share. Gross proceeds to EyePoint in the
offering, before underwriting discounts and estimated expenses of
the offering, were approximately $230.0 million.
J.P. Morgan, TD Cowen and Guggenheim Securities
acted as joint book running managers for the offering. Cantor also
acted as a book running manager for the offering. Mizuho and
Laidlaw & Company (UK) Ltd. acted as co-managers for the
offering.
EyePoint intends to use the net proceeds from
the offering to advance clinical development of EYP-1901 for wet
age related macular degeneration through the initiation of and
reporting of topline data from two pivotal Phase 3 clinical trials,
as well as support its earlier stage pipeline development
initiatives, and for general corporate purposes.
The securities described above were offered by
EyePoint pursuant to a shelf registration statement on Form S-3
(No. 333-275125) previously filed with the Securities and Exchange
Commission (SEC) on October 20, 2023 and declared effective by the
SEC on October 30, 2023.
The securities were offered by means of a
prospectus supplement and accompanying prospectus relating to the
offering that form a part of the registration statement. A final
prospectus supplement relating to and describing the terms of the
offering has been filed with the SEC and is available on the SEC’s
website at www.sec.gov. Copies of the final prospectus supplement
and accompanying prospectus relating to the offering may be
obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by
telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by email at
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926;
Guggenheim Securities, LLC, Attention: Equity Syndicate Department,
330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone
at (212) 518-9544, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com; or Cantor
Fitzgerald & Co., Attention: Capital Markets, 110 East 59th
Street, 6th Floor, New York, New York 10022, or by e-mail at
prospectus@cantor.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any of the
securities described herein, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a
clinical-stage company committed to developing and commercializing
therapeutics to help improve the lives of patients with serious
retinal diseases. The Company's pipeline leverages its proprietary
bioerodible Durasert E™ technology for sustained intraocular drug
delivery. The company’s lead product candidate, EYP-1901, is an
investigational sustained delivery treatment for VEGF-mediated
retinal diseases combining vorolanib, a selective and
patent-protected tyrosine kinase inhibitor (TKI) with Durasert E™.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences
for the localized treatment of all ophthalmic diseases. Additional
pipeline programs include EYP-2301, a promising Tie-2 activator,
razuprotafib, f/k/a AKB-9778, formulated in Durasert E™ to
potentially improve outcomes in wet AMD and diabetic eye disease.
The proven Durasert® drug delivery platform has been safely
administered to over thousands of patient eyes across four U.S. FDA
approved products. EyePoint Pharmaceuticals is headquartered in
Watertown, Massachusetts.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE
SECURITIES LITIGATION ACT OF 1995: To the extent any statements
made in this press release deal with information that is not
historical, these are forward-looking statements under the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements regarding the use of proceeds
for the offering and other statements identified by words such as
“will,” “potential,” “could,” “can,” “believe,” “intends,”
“continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,”
other words of similar meaning or the use of future dates.
Forward-looking statements by their nature address matters that
are, to different degrees, uncertain. Uncertainties and risks may
cause EyePoint’s actual results to be materially different than
those expressed in or implied by EyePoint’s forward-looking
statements. For EyePoint, this includes stock price volatility and
uncertainties relating to the financial markets, the medical
community and the global economy, and the impact of instability in
general business and economic conditions, including changes in
inflation, interest rates and the labor market. More detailed
information on these and additional factors that could affect
EyePoint’s actual results are described in EyePoint’s filings with
the SEC, including its Annual Report on Form 10-K for the
fiscal year ended December 31, 2022, as revised or supplemented by
its Quarterly Reports on Form 10-Q and other documents filed with
the SEC. All forward-looking statements in this news release speak
only as of the date of this news release. EyePoint undertakes no
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Investors:Christina TartagliaStern
IRDirect: 212-698-8700christina.tartaglia@sternir.com
Media ContactAmy PhillipsGreen
Room CommunicationsDirect:
412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfica de Acción Histórica
De May 2023 a May 2024